LLY

1,013

-0.56%↓

JNJ

245.32

+0.76%↑

ABBV

223.81

-1.41%↓

NVS

163.17

-1.04%↓

MRK

120.91

+0.23%↑

LLY

1,013

-0.56%↓

JNJ

245.32

+0.76%↑

ABBV

223.81

-1.41%↓

NVS

163.17

-1.04%↓

MRK

120.91

+0.23%↑

LLY

1,013

-0.56%↓

JNJ

245.32

+0.76%↑

ABBV

223.81

-1.41%↓

NVS

163.17

-1.04%↓

MRK

120.91

+0.23%↑

LLY

1,013

-0.56%↓

JNJ

245.32

+0.76%↑

ABBV

223.81

-1.41%↓

NVS

163.17

-1.04%↓

MRK

120.91

+0.23%↑

LLY

1,013

-0.56%↓

JNJ

245.32

+0.76%↑

ABBV

223.81

-1.41%↓

NVS

163.17

-1.04%↓

MRK

120.91

+0.23%↑

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Open

1.25 3.31

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.19

Max

1.27

Schlüsselkennzahlen
By Trading Economics
Einkommen	17M -26M
Angestellte	171
EBITDA	19M -23M

Dividenden
By Dow Jones
Nächstes Ergebnis	26. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-34M 68M
Vorheriger Eröffnungskurs	-2.06
Vorheriger Schlusskurs	1.25

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Feb. 2026, 22:31 UTC

Ergebnisse

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

18. Feb. 2026, 22:18 UTC

Ergebnisse

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

18. Feb. 2026, 22:11 UTC

Ergebnisse

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

18. Feb. 2026, 21:52 UTC

Ergebnisse

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

18. Feb. 2026, 23:56 UTC

Market Talk

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

18. Feb. 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. Feb. 2026, 23:46 UTC

Market Talk

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

18. Feb. 2026, 23:34 UTC

Market Talk

Ergebnisse

Brambles' Cost Control Stands Out to Bull -- Market Talk

18. Feb. 2026, 23:33 UTC

Market Talk

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

18. Feb. 2026, 23:32 UTC

Market Talk

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

18. Feb. 2026, 22:45 UTC

Ergebnisse

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

18. Feb. 2026, 22:44 UTC

Market Talk

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

18. Feb. 2026, 22:37 UTC

Ergebnisse

Nutrien 4Q EPS $1.18 >NTR.T

18. Feb. 2026, 22:37 UTC

Ergebnisse

Nutrien 4Q Sales $5.34B >NTR.T

18. Feb. 2026, 22:35 UTC

Ergebnisse

Pan American Silver 4Q EPS $1.07 >PAAS

18. Feb. 2026, 22:35 UTC

Ergebnisse

Pan American Silver 4Q Rev $1.18B >PAAS

18. Feb. 2026, 22:30 UTC

Ergebnisse

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

18. Feb. 2026, 22:29 UTC

Ergebnisse

Kinross Gold 4Q EPS 75c >K.T

18. Feb. 2026, 22:22 UTC

Ergebnisse

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

18. Feb. 2026, 22:22 UTC

Market Talk

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

18. Feb. 2026, 22:16 UTC

Ergebnisse

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

18. Feb. 2026, 22:05 UTC

Ergebnisse

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

18. Feb. 2026, 22:03 UTC

Ergebnisse

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

18. Feb. 2026, 22:02 UTC

Ergebnisse

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

18. Feb. 2026, 22:02 UTC

Ergebnisse

Kaiser Aluminum 4Q Sales $929M >KALU

18. Feb. 2026, 22:02 UTC

Ergebnisse

Kaiser Aluminum 4Q EPS $1.68 >KALU

18. Feb. 2026, 22:00 UTC

Ergebnisse

Kinross Gold 4Q Adj EPS 67c >KGC

18. Feb. 2026, 22:00 UTC

Ergebnisse

Kinross Gold 4Q Sales $2.02B >KGC

18. Feb. 2026, 21:56 UTC

Ergebnisse

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

18. Feb. 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Rating-Konsens

By TipRanks

Sell

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.